Dashboard
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 22.81%
- Company has a low Debt to Equity ratio (avg) at 0 times
Positive results in Sep 26
Stock is technically in a Bearish range
With ROE of 21.4, it has a Very Expensive valuation with a 17.5 Price to Book Value
Increasing Participation by Institutional Investors
Stock DNA
Pharmaceuticals & Biotechnology
INR 15,188 Cr (Small Cap)
82.00
40
0.59%
-0.54
21.42%
17.41
Total Returns (Price + Dividend) 
Latest dividend: 35.83219514591726 per share ex-dividend date: Jul-31-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Astrazeneca Pharma India Ltd is Rated Hold
Astrazeneca Pharma India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read More
Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid Technical Downgrade
Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s stock price has declined sharply, reflecting a downgrade in its technical grade from Sell to Hold, amid a broader context of subdued market performance and sector-specific pressures.
Read More
Astrazeneca Pharma India Ltd is Rated Hold
Astrazeneca Pharma India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 November 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Letter Of Intent With Strand Life Sciences Private Limited - Disclosure Of Linkedin Communication
17-Nov-2026 | Source : BSEPlease find the enclosed intimation of the Company as per the captioned subject for your reference.
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
17-Nov-2026 | Source : BSEPlease find the enclosed document of the Company as per the captioned subject for your reference.
Revised Submission With Functional Link - Letter Of Intent With Strand Life Sciences Private Limited - Disclosure Of Linkedin Communication
17-Nov-2026 | Source : BSEPlease find the enclosed document of the Company as per the captioned subject. This is being resubmitted as the weblink was not correctly re-directing to the relevant web page in the earlier submission. Kindly take this submission on record.
Corporate Actions 
No Upcoming Board Meetings
Astrazeneca Pharma India Ltd has declared 1800% dividend, ex-date: 31 Jul 26
Astrazeneca Pharma India Ltd has announced 2:10 stock split, ex-date: 15 Jun 06
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 7 Schemes (7.01%)
Held by 93 FIIs (2.64%)
Astrazeneca Ab (0.0%)
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund(various Schemes) (2.9%)
12.82%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 6.78% vs 18.01% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 64.33% vs -15.49% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 36.44% vs 31.16% in Sep 2024
Growth in half year ended Sep 2025 is 313.10% vs -74.92% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 37.32% vs 35.46% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 148.11% vs -52.89% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025